Research and analysis

Consideration of barriers to research: part 2

Recommendations from the ACMD to reduce barriers to research for schedule 1 controlled drugs.

• From: Advisory Council on the Misuse of Drugs
• Published: 22 December 2023
• Last updated: 6 February 2024 — See all updates

Documents

Consideration of barriers to research part 2: schedule 1 controlled drugs (accessible version)

HTML

Consideration of barriers to research part 2: schedule 1 controlled drugs

PDF, 380 KB, 27 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

On 12 December 2022 the ACMD was commissioned by the Minister of State for Crime, Policing and Fire to provide advice to reduce barriers to research for all schedule 1 controlled drugs.

This follows ACMD advice in 2021 to reduce barriers to research for synthetic cannabinoid receptor agonists (SCRAs) (Consideration of barriers to research: part 1). After collecting evidence from the research community, the ACMD formulated several options to reduce barriers to research for schedule 1 controlled drugs in academia and industry.

The ACMD has recommended a series of options that could provide solutions in the short term, alongside further options for government to consider.

Published 22 December 2023
Last updated 6 February 2024 + show all updates

1. 6 February 2024

   Added accessible version of consideration of barriers to research part 2: schedule 1 controlled drugs.

2. 22 December 2023

   First published.